Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Vizsgálati helyszín

Northwest Clinical Research Center

Bellevue, Washington 98007, Egyesült ÁllamokMég nincs intézményhez kötve

36futó vizsgálat
34lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 70 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Alzheimer-kór17 vizsgálat
Depresszió15 vizsgálat
Elhízás15 vizsgálat
Migrén10 vizsgálat
Osteoarthritis7 vizsgálat
Skizofrénia7 vizsgálat
2-es típusú cukorbetegség5 vizsgálat
Bipoláris zavar5 vizsgálat
Obstructive sleep apnoea5 vizsgálat
Autizmus spektrumzavar2 vizsgálat
Atópiás dermatitisz (ekcéma)1 vizsgálat
Fázis: 3. fázis43 vizsgálat
2. fázis22 vizsgálat
2/3. fázis2 vizsgálat
4. fázis2 vizsgálat
Állapot: Lezárult25 vizsgálat
Toboroz22 vizsgálat
Fut, nem toboroz13 vizsgálat
Leállították7 vizsgálat
Visszavonták2 vizsgálat
Még nem toboroz1 vizsgálat
Fő szponzor: Eli Lilly and Company27 vizsgálat
Intra-Cellular Therapies, Inc.5 vizsgálat
Janssen Research & Development, LLC5 vizsgálat
Pfizer5 vizsgálat
Amgen3 vizsgálat
és még 15

Futó vizsgálatok

Még nem toboroz
A Study of Brenipatide in Participants With Major Depressive Disorder
NCT07928245· 2. fázis· Eli Lilly and Company· Forrás
Contact: Wisam Al jumaili (principal investigator)
Toboroz
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· 3. fázis· Eli Lilly and Company· Forrás
Contact: Wisam Al jumaili (principal investigator)
Toboroz
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
NCT07716098· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
NCT07641517· 2. fázis· Eli Lilly and Company· Forrás
Contact: Arifulla Khan, MD (principal investigator)
Toboroz
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582· 3. fázis· Eli Lilly and Company· Forrás
Contact: Jeena Vaid (principal investigator)
Toboroz
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630· 3. fázis· Novo Nordisk A/S· Forrás
Contact: Novo Nordisk
Toboroz
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507· 2. fázis· Eli Lilly and Company· Forrás
Contact: Arun Arora (principal investigator)
Toboroz
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756· 3. fázis· Eli Lilly and Company· Forrás
Contact: Arun Arora (principal investigator)
Toboroz
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305· 2. fázis· LB Pharmaceuticals Inc.· Forrás
Contact: Kimberlee Wheeler
Fut, nem toboroz
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765· 3. fázis· Amgen· Forrás
Toboroz
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175· 2. fázis· Eli Lilly and Company· Forrás
Contact: Wisam Al jumaili (principal investigator)
Fut, nem toboroz
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884· 3. fázis· Eli Lilly and Company· Forrás
Contact: Ann Kolwitz (principal investigator)
Fut, nem toboroz
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321· 2. fázis· Lighthouse Pharmaceuticals, Inc.· Forrás
Contact: Study Coordinator
Toboroz
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Contact: Wisam Al Jumaili, Site 1253
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141· 3. fázis· Pfizer· Forrás
Toboroz
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292· 2. fázis· Eli Lilly and Company· Forrás
Contact: Arifulla Khan, MD (principal investigator)
Fut, nem toboroz
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Escitalopram for Agitation in Alzheimer's Disease
NCT03108846· 3. fázis· JHSPH Center for Clinical Trials· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Depresszió7 toboroz
Alzheimer-kór4 toboroz
Bipoláris zavar4 toboroz
Osteoarthritis4 toboroz
Skizofrénia4 toboroz
Elhízás3 toboroz
Autizmus spektrumzavar2 toboroz
Migrén2 toboroz

Lezárt vizsgálatok

Lezárult
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
NCT07258485· Janssen Research & Development, LLC· Forrás
Visszavonták
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489· 2. fázis· Syndeio Biosciences, Inc· Forrás
Contact: Karen Raudibaugh
Lezárult
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
NCT06603623· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Lezárult
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344· 2. fázis· Boehringer Ingelheim· Forrás
Lezárult
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
NCT06568042· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
NCT06423781· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Lezárult
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Lezárult
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
NCT06373146· 2. fázis· Eli Lilly and Company· Forrás
Leállították
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
NCT06304883· 3. fázis· Alzheon Inc.· Forrás
Lezárult
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612· 2. fázis· Sirtsei Pharmaceuticals, Inc.· Forrás
Lezárult
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05704738· 3. fázis· Amgen· Forrás
Lezárult
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123· 4. fázis· Pfizer· Forrás
Leállították
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NCT05575076· 3. fázis· Cassava Sciences, Inc.· Forrás
Lezárult
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400· 4. fázis· Pfizer· Forrás
Lezárult
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05455684· 3. fázis· Janssen Research & Development, LLC· Forrás
Leállították
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
NCT05267535· 2/3. fázis· Neurim Pharmaceuticals Ltd.· Forrás
Lezárult
A Study of JNJ-55308942 in the Treatment of Bipolar Depression
NCT05328297· 2. fázis· Janssen Pharmaceutica N.V., Belgium· Forrás
Leállították
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT05026177· 3. fázis· Cassava Sciences, Inc.· Forrás
Lezárult
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05145413· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Leállították
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
NCT05016661· 2. fázis· AEON Biopharma, Inc.· Forrás
Lezárult
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
NCT04846881· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
NCT04820309· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Lezárult
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
NCT04770220· 3. fázis· Alzheon Inc.· Forrás
Leállították
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
NCT04804033· 2/3. fázis· Pfizer· Forrás
Lezárult
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
NCT04845178· 2. fázis· AEON Biopharma, Inc.· Forrás
Lezárult
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT03393520· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Leállították
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 13.